Removing zelnecirnon means the biotech’s sole remaining clinical-stage asset is tivumecirnon, a phase 2 oncology med being ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

Fountain Life, a longevity, preventative health, advanced diagnostics, and therapeutics company, today announced that it has ...

Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: Median Overall Survival is 32.9 ...

Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® ...

While immunotherapies have transformed treatment of many types of cancer, they do sometimes fail to have an impact – as Merck & Co has just observed in a study of Keytruda in head and neck cancer.

Merck & Co's FDA approval for Keytruda in advanced liver cancer looks secure, after an Asian clinical trial found that the cancer immunotherapy improved survival in these patients. Keytruda ...

News updates from November 13: US inflation rose to 2.6% in October; Donald Trump picks Matt Gaetz as attorney-general on facebook (opens in a new window) News updates from November 13: US inflation ...

and both trials were placed on clinical hold by the U.S. Food and Drug Administration in February 2024 due to a serious adverse event of liver injury requiring transplant in one patient in the AD ...

After hours: 8 November at 18:48 GMT-5 ...

After hours: 8 November at 6:48 pm GMT-5 ...